{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T23:34:55Z","timestamp":1770507295980,"version":"3.49.0"},"reference-count":42,"publisher":"Informa UK Limited","issue":"17","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Future Oncol."],"published-print":{"date-parts":[[2015,9,30]]},"DOI":"10.2217\/fon.15.118","type":"journal-article","created":{"date-parts":[[2015,8,14]],"date-time":"2015-08-14T14:32:24Z","timestamp":1439562744000},"page":"2471-2484","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":62,"title":["Risk of Cutaneous Toxicities in Patients with Solid Tumors Treated with Immune Checkpoint Inhibitors: A Meta-Analysis"],"prefix":"10.1080","volume":"11","author":[{"given":"Omar","family":"Abdel-Rahman","sequence":"first","affiliation":[{"name":"Clinical Oncology Department, Faculty of Medicine, Ain Shams University, Cairo, Egypt"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hesham","family":"ElHalawani","sequence":"additional","affiliation":[{"name":"Clinical Oncology Department, Faculty of Medicine, Ain Shams University, Cairo, Egypt"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mona","family":"Fouad","sequence":"additional","affiliation":[{"name":"Medical Microbiology & Immunology Department, Faculty of Medicine, Ain Shams University, Cairo, Egypt"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2015,8,14]]},"reference":[{"key":"e_1_3_3_3_1","doi-asserted-by":"publisher","DOI":"10.2147\/PGPM.S53163"},{"key":"e_1_3_3_4_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1104621"},{"key":"e_1_3_3_5_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1003466"},{"key":"e_1_3_3_6_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1305133"},{"key":"e_1_3_3_7_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-07-4079"},{"key":"e_1_3_3_8_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.48.3685"},{"key":"e_1_3_3_9_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1200694"},{"key":"e_1_3_3_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(13)70551-5"},{"key":"e_1_3_3_11_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-151-4-200908180-00135"},{"key":"e_1_3_3_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/0197-2456(86)90046-2"},{"key":"e_1_3_3_13_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.327.7414.557"},{"key":"e_1_3_3_14_1","volume-title":"50th Annual Meeting of American Society of Clinical Oncology","author":"Eggermont AM","year":"2014","unstructured":"Eggermont AM , Chiarion-SileniV, GrobJJet al. Efficacy, safety, and quality of life (QoL) data from the EORTC 18071 Phase III trial of ipilimumab (Ipi) versus placebo after complete resection of stage III melanoma. Presented at: 50th Annual Meeting of American Society of Clinical Oncology. Chicago, USA, 30 May\u20133 June 2014."},{"key":"e_1_3_3_15_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.38.4032"},{"key":"e_1_3_3_16_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.44.6112"},{"key":"e_1_3_3_17_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1412082"},{"key":"e_1_3_3_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)70189-5"},{"key":"e_1_3_3_19_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mds213"},{"key":"e_1_3_3_20_1","volume-title":"European Society for Medical Oncology 2014 Congress","author":"Weber JS","year":"2014","unstructured":"Weber JS , MinorD, D\u2019Angeloet al. A Phase 3 randomized, open-label study of nivolumab (anti-PD-1; BMS-936558; ONO-4538) versus investigator\u2019s choice chemotherapy (ICC) in patients with advanced melanoma after prior anti-CTLA-4 therapy. Presented at: European Society for Medical Oncology 2014 Congress. Madrid, Spain, 26\u201330 September 2014."},{"key":"e_1_3_3_21_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2014.13943"},{"key":"e_1_3_3_22_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-009-9376-8"},{"key":"e_1_3_3_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)60958-2"},{"key":"e_1_3_3_24_1","doi-asserted-by":"publisher","DOI":"10.1189\/jlb.1212621"},{"key":"e_1_3_3_25_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.157.11.4762"},{"key":"e_1_3_3_26_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1200690"},{"key":"e_1_3_3_27_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature13954"},{"key":"e_1_3_3_28_1","doi-asserted-by":"publisher","DOI":"10.1185\/03007995.2015.1020367"},{"key":"e_1_3_3_29_1","doi-asserted-by":"publisher","DOI":"10.1586\/14737140.2015.985660"},{"key":"e_1_3_3_30_1","doi-asserted-by":"publisher","DOI":"10.1586\/14737140.2014.953936"},{"key":"e_1_3_3_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2014.02.035"},{"key":"e_1_3_3_32_1","volume-title":"Perspectives in Melanoma XII","author":"Lebbe\u00b4 C","year":"2008","unstructured":"Lebbe\u00b4 C , O\u2019DayS, Chiarion SileniVet al. Analysis of the onset and resolution of immunerelated adverse events during treatment with ipilimumab in patients with metastatic melanoma. Presented at: Perspectives in Melanoma XII. Scheveningen\/The Hague, the Netherlands, 1\u20134 October 2008."},{"key":"e_1_3_3_33_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.27969"},{"key":"e_1_3_3_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(09)70334-1"},{"key":"e_1_3_3_35_1","article-title":"Ipilimumab may increase the severity of cutenaous toxicity related to radiotherapy","author":"Ery\u0131lmaz MK","year":"2015","unstructured":"Ery\u0131lmaz MK , MutluH, SalimDKet al. Ipilimumab may increase the severity of cutenaous toxicity related to radiotherapy. J. Oncol. Pharm. Pract. pii: 10.8155215572930 (2015) (Epub ahead of print).","journal-title":"J. Oncol. Pharm. Pract."},{"key":"e_1_3_3_36_1","doi-asserted-by":"publisher","DOI":"10.1097\/CMR.0000000000000018"},{"key":"e_1_3_3_37_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1114329"},{"key":"e_1_3_3_38_1","doi-asserted-by":"publisher","DOI":"10.2214\/AJR.10.6198"},{"key":"e_1_3_3_39_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.57.4756"},{"key":"e_1_3_3_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2012.12.963"},{"key":"e_1_3_3_41_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.41.6750"},{"key":"e_1_3_3_42_1","volume-title":"ASCO Annual Meeting","author":"Baurain J-F","year":"2012","unstructured":"Baurain J-F , SmylieM, AsciertoPet al. Outcomes of ipilimumab treatment-related adverse events in patients with metastatic melanoma (mm) who received systemic corticosteroids in a Phase III trial. Presented at: ASCO Annual Meeting. Chicago, IL, USA, 30, 1\u20135 June 2012."},{"key":"e_1_3_3_43_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2014.06.042"},{"key":"e_1_3_3_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(09)70334-1"}],"container-title":["Future Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.2217\/fon.15.118","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,23]],"date-time":"2024-06-23T06:42:31Z","timestamp":1719124951000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.2217\/fon.15.118"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,8,14]]},"references-count":42,"journal-issue":{"issue":"17","published-print":{"date-parts":[[2015,9,30]]}},"alternative-id":["10.2217\/fon.15.118"],"URL":"https:\/\/doi.org\/10.2217\/fon.15.118","relation":{},"ISSN":["1479-6694","1744-8301"],"issn-type":[{"value":"1479-6694","type":"print"},{"value":"1744-8301","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,8,14]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2015-08-14","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}